To evaluate the safety and efficacy of HER2 CAR-T cells in relapsed or refractory sarcoma, including OS, a clinical trial confirmed the stabilization of patients for several months with a dose of 1 × 108/m2 HER2 CAR-T cells, which was considered to be the optimal and well-tolerated dose. This evidence concerns the gene ERBB2 and sarcoma.